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Abstract
Biallelic mutations of the alsin Rho guanine nucleotide exchange factor (ALS2) gene cause a group of overlapping autosomal
recessive neurodegenerative disorders including infantile-onset ascending hereditary spastic paralysis (IAHSP), juvenile primary
lateral sclerosis (JPLS), and juvenile amyotrophic lateral sclerosis (JALS/ALS2), caused by retrograde degeneration of the upper
motor neurons of the pyramidal tracts. Here, we describe 11 individuals with IAHSP, aged 2–48 years, with IAHSP from three
unrelated consanguineous Iranian families carrying the homozygous c.1640+1G>A founder mutation in ALS2. Three affected
siblings from one family exhibit generalized dystonia which has not been previously described in families with IAHSP and has
only been reported in three unrelated consanguineous families with JALS/ALS2. We report the oldest individuals with IAHSP to
date and provide evidence that these patients survive well into their late 40s with preserved cognition and normal eye movements.
Our study delineates the phenotypic spectrum of IAHSP and ALS2-related disorders and provides valuable insights into the
natural disease course.
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Introduction
Retrograde degeneration of the upper motor neurons (UMN)
of the pyramidal tracts due to biallelic pathogenic ALS2
(OMIM * 606352) variants has been associated with a clinical
continuum ranging from infantile-onset ascending hereditary
spastic paralysis (IAHSP, OMIM # 607225) to juvenile forms
without lower motor neuron (LMN) involvement (juvenile
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primary lateral sclerosis (JPLS, OMIM # 606353)), and juve-
nile forms with LMN involvement (autosomal recessive juve-
nile amyotrophic lateral sclerosis (JALS/ALS2, OMIM #
205100)) [1–4].
The ALS2 (alsin Rho guanine nucleotide exchange
factor) gene, also known as KIAA1563, is located at
2q33.1 and encodes at least two isoforms of the alsin
protein, a long form with 1657 amino acids and a short
form with 396 amino acids. Both forms are ubiquitously
expressed in various tissues, including the brain and spi-
nal cord [1, 2]. Alsin is a member of the guanine nucle-
otide exchange factors (GEFs) and can activate Rho,
Rac1, and Rab5 GTPases. The protein contains three main
(GEF) domains: the N-terminal regulator of chromatin
condensation (RCC1)-like domain, the central Dbl homol-
ogy and pleckstrin homology (DH/PH) domain, and the
C-terminal vacuolar protein sorting 9 (VPS9) domain
[1–3, 5–9]. Alsin plays a role in endosomal and mitochon-
drial trafficking as well as cytoskeleton maintenance and
endocytosis [5–9].
Here, we report a novel homozygous splice site ALS2 path-
ogenic variant, identified using exome sequencing, in 11 indi-
viduals with IAHSP from three unrelated consanguineous
Iranian families.
Materials and methods
This study was approved by the local ethics committee/
Institutional Review Board at Ahvaz Jundishapur University
ofMedical Sciences, and informed consent was obtained from
the three participating families. Members of these families
were recruited through the Narges and Noor Medical
Genetic Diagnostic Laboratories in Ahvaz, Iran.
Exome sequencing was performed on genomic DNA
extracted from blood from the proband of each family
(IV:1 in family 1, III:6 in family 2, and IV:1 in family
3). Exome library preparation, sequencing, bioinformat-
ics, and data analysis were performed as previously de-
scribed [10]. Based on the assumption that the disease
follows an autosomal recessive inheritance pattern as well
as the presence of consanguinity in these families, homo-
zygous potentially deleterious variants residing within re-
gions of homozygosity (> 2 Mb) were prioritized. These
variants were screened through publically available popu-
lation databases and our in-house database generated for
variant frequency in the Iranian population. Synonymous
variants, intronic variants (> 5 bp from exon boundaries),
and common variants (minor allele frequency > 0.001%)
were excluded. Validation and segregation analysis were
performed using Sanger sequencing.
Results
Genomic analyses
Exome sequencing revealed a novel homozygous ALS2
canonical splice site variant, NM_020919.3: c.1640+
1G>A, located in a large homozygous identical-by-
descent (IBD) region and co-segregating with IAHSP in
the affected siblings, unaffected parents (heterozygous
carriers), and healthy siblings (heterozygous carriers and
homozygous wild type) in the three families (Fig. 1). The
variant is not present in ExAC (Exome Aggregation
Consortium, http://exac.broadinstitute.org; accessed
February 2018), gnomAD (genome Aggregation
Database, http://gnomad.broadinstitute.org; accessed
February 2018), GME Variome (Greater Middle East
Variome Project, http://igm.ucsd.edu/gme; accessed
February 2018), or Iranome (http://iranome.com;
accessed February 2018) and was absent from ~ 2000
Iranian control alleles. The variant is present on a
common haplotype and represents a founder mutation.
The clinical features of all 11 affected individuals are
summarized in Table 1.
Family 1
Family 1 consists of two affected and one unaffected sib-
ling born to healthy consanguineous Iranian parents of
Arab descent (Table 1; Fig. 1a). The two affected siblings
had no history of prenatal, perinatal, or neonatal compli-
cations. They sat independently at approximately 6 months
old and spoke at the age of 1.5 years. However, they
developed mild developmental delay in the second year.
They were only able to walk with assistance at 1.5 years
and never attained independent walking. Both siblings
demonstrated regression with dysarthria and progression
to spastic tetraparesis. They have normal cognition, hear-
ing, and vision. They do not have dysphagia, abnormal
eye movements, or sensory abnormalities.
Patient IV:1, the proband in family 1, is a 5-year-old male.
He developed significant ankle contractures and became
wheelchair bound at 4 years old after losing the ability to walk
with support despite Achilles tendon release. On examination,
he had dysarthria, mild atrophy of the distal limb muscles,
weakness of the shoulder girdle muscles, spastic tetraparesis,
hyperreflexia, sustained clonus, and bilateral extensor plantar
responses. His metabolic testing and brain MRI were normal
at the age of 3 years. Results of his electromyography were
suggestive of UMN disease.
Patient IV:2 is a 2-year-old female who has a similar phe-
notype to her older brother IV:1, but she is not restricted to a
wheelchair.
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Family 2
Family 2 consists of three affected sisters with IAHSP and
generalized dystonia as well as six unaffected siblings
born to healthy consanguineous Iranian parents of Arab
descent (Table 1; Fig. 1b). The three affected females
presented with similar clinical findings but with variable
age of onset and disease progression. They all have nor-
mal cognition, eye movements, bowel and bladder conti-
nence, and motor coordination. Motor and sensory nerve
conduction studies (NCS) were normal.
The proband in family 2, patient III:6, is a 17-year-old
female with a history of normal motor and speech devel-
opment. She sat and walked unsupported at 6 months and
1 year old respectively. However, her development
slowed, and she began to regress during the second year
of life. Ascending spastic paresis presented with unilateral
leg claudication at the age of 1.5 years. She progressed to
spastic tetraparesis and eventually became wheelchair
bound at 6 years old. She developed dysarthria at 7,
which progressed to anarthria at the age of 8. She also
developed other bulbar and pseudobulbar signs as well as
opisthotonus at 8 years old.
Patients III:4 and III:8, a 26- and 13-year-old female
respectively, unlike their sister (proband III:6), had a his-
tory of early onset developmental delay and regression.
They never achieved the ability to sit or walk indepen-
dently, and while they made some vocalizations, they nev-
er developed speech. They developed ascending spastic
paraparesis during the first year of life. Their condition
progressed to spastic tetraparesis and they eventually be-
came wheelchair bound at the age of 6 years. Other bulbar
and pseudobulbar signs as well as opisthotonus were pres-
ent from the age of 7 years for III:4 and before the age of
2 years for III:8. The youngest sister, III:8, had a normal
brain MRI.
Fig. 1 Pedigrees of the described families. a Pedigree of family 1. b
Pedigree of family 2. c Pedigree of family 3. An arrow indicates the
proband in each family. d Electropherograms of different individuals in
the three Iranian families showing affected members are homozygous for
the c.1640+1G>A variant (top), unaffected carriers are heterozygous for
the variant (middle), and unaffected non-carriers are homozygous for the
wild type allele (bottom)
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Family 3
Family 3 consists of seven affected individuals (six with ge-
netic testing) from a large consanguineous Iranian family of
Arab descent (Table 1; Fig. 1c). All the patients presented with
developmental delay and regression as well as progression to
spastic tetraparesis.
Patient IV:1, the proband in family 3, is a 7-year-old female
and the first child of her healthy consanguineous Arab parents.
She sat unsupported at the age of 9 months. She was late to
crawl and was only able to stand with support after starting
Table 1 Clinical features of the described individuals
Family Family 1 Family 2 Family 3
Patient IV:1 IV:2 III:4 III:6 III:8 IV:1 III:7 III:8 III:9 III:10 III:18
Age at onset < 1.5 yr < 1.5 yr < 1 yr 1.5 yr < 1 yr < 1.5 yr < 1.5 yr < 1.5 yr < 1.5 yr < 1.5 yr < 1.5 yr
Age at last exam 5 yr 2 yr 26 yr 17 yr 13 yr 7 yr 48 yr 46 yr 45 yr 42 yr 38 yr
Gender M F F F F F M F M F F
Growth N N N N N N Abn† Abn† Abn† Abn† Abn†
Regression + + + + + + + + + + +
GDD + + + + + + + + + + +
Cognition* N N N N N N N N N N N
Age at sitting 6 mo 6 mo NS 6 mo NS 9 mo 9 mo 9 mo 9 mo 9 mo NS
Age at walking NW NW NW 1 yr NW NW NW NW NW NW NW
Wheelchair bound 4 yr − 6 yr 6 yr 6 yr + +‡ +‡ +‡ +‡ +‡
Age at talking 1.5 yr 1.5 yr NT NA NT 1.5 yr 1.5 yr 1.5 yr 1.5 yr 1.5 yr 3 yr
Dysarthria + + NT 7 yr NT 6 yr + + + + +
Anarthria − − NT 8 yr NT 7 yr + + + + 5 yr
Dysphagia/drooling −/− −/− 7 yr/− 8 yr/− < 2 yr/− 6 yr/− 5–7 yr/+ 5–7 yr/+ 5–7 yr/+ 5–7 yr/+ 6–7 yr/+
Ocular movements N N N N N N N N N N N
Facial muscle spasticity/Trismus −/− −/− −/+ −/+ −/+ ± +/+ +/+ +/+ +/− ±
Facial dystonia − − + + + − − − − − −
Generalized dystonia − − + + + − − − − − −
Opisthotonus − − 7 yr 8 yr < 2 yr − − − − − −
Fasciculations − − − − − − − − − − −
Muscle atrophy + − − − − + + + + + +
Spastic paraparesis + + + + + + + + + + +
Spastic tetraparesis + + + + + + + + + + +
Hyperreflexia + + + + + + + + + + +
Clonus + + − − − + + + + + +
Extensor plantar responses + + + + + + + + + + +
Incontinence − − − − − − + + + + +
Emotional lability¶ − − + + + + + + + + +
Cerebellar signs NA NA − − − − NA NA NA NA NA
Scoliosis − − − − − + + + + +
Brain MRI N NA NA NA N N Abn§ NA NA NA NA
NCS N N N N N N NA NA NA NA NA
(+), present; (−), absent; yr, year(s); mo, months; F, female; M, male; N, normal; Abn, abnormal; GDD, global developmental delay; NCS, nerve
conduction studies; NA, not available or not assessed; NS, never attained/achieved independent sitting; NT, never attained/achieved talking; NW, never
attained/achieved independent walking
†Cachexic
‡Bedbound at the age of ~ 12 years
§Mild cerebral atrophy
¶ Includes uncontrolled laughter and/or uncontrolled weeping
*Assessed based on ormal social interaction with other family members based on the gestures and facial expressions
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occupational therapy at 18 months old. She developed ankle
contractures and never attained the ability to walk indepen-
dently. She developed mild dysphagia and dysarthria at the
age of 6 years. When examined at 7 years old, anarthria,
pseudobulbar palsy, elbow flexion contractures, and mild at-
rophy of the distal limb muscles were evident. She had mild
facial muscle weakness, shoulder girdle muscle weakness,
spastic tetraparesis, hyperreflexia, sustained clonus, and bilat-
eral extensor plantar responses. She demonstrated assisted toe
walking with a spastic gait. Cognition, eye movements, and
cerebellar examination were normal. There were no sensory,
visual, or hearing deficits. Her neurometabolic workup and
electromyography at the age of 2 years were normal. Her brain
MRI was also normal.
Patients III:7–10 are four affected siblings (2 males and 2
females) aged between 42 and 48 years. They sat unsupported
at 9 months old. Global developmental delay was recognized
during the second year of life. They developed dysarthria and
progressive spastic paraparesis never achieving the ability to
stand or walk unsupported. Their clinical course deteriorated
rapidly with upper limb, bulbar, and pseudobulbar involve-
ment. They developed anarthria, severe dysphagia, trismus
(only two of the older siblings), and incontinence, becoming
bedbound at approximately 12 years old. On their last exam-
ination, theywere cachectic with evidence of profoundmuscle
atrophy of the distal limbs and flexion contractures of the
knees and ankles. They had facial muscle weakness, spastic
tetraparesis, hyperreflexia, sustained clonus, bilateral extensor
plantar responses, and mild scoliosis. Their cognition and oc-
ular movements were normal. Brain MRI of the oldest sibling
at the age of 47 years showed mild cerebral atrophy.
Patient III:18 is a 38-year-old female who has a similar
phenotype to her affected relatives (four siblings, III:7–10)
except that she had an earlier onset of developmental delay
and regression. Unlike her affected relatives, she never
achieved the ability to sit independently and spoke her first
word at 3 years old. She only used single words and developed
dysarthria which progressed to anarthria at the age of 5 years.
Videos of the patients from these three families can be made
available on request.
Discussion
Here, we present phenotypic data for 11 affected individuals
with IAHSP from three independent Iranian families, all of
whom share an identical novel ALS2 canonical splice site
mutation (Table 1). Mutations in the ALS2 gene have been
associated with a phenotypic spectrum ranging from infantile
forms with both UMN and LMN involvement (IAHSP) to
juvenile forms with (JALS/ALS2) or without (JPLS) LMN
involvement [1–4, 11, 12]. To date, approximately 50 ALS2
pathogenic variants have been reported in individuals with
ALS2-related disorders and include missense, nonsense,
frameshift, and splice site variants that are thought to result
in loss of function [12]. At least 22 of the reported ALS2
pathogenic variants have been associated with IAHSP and
have been described in a total of 42 individuals. The majority
of reported cases originate from the Middle East and
Mediterranean countries [2–4, 11–25]. Table 2 provides a
summary of the mutations and clinical features of the previ-
ously reported IAHSP cases.
IAHSP is characterized by the onset of spastic paraparesis
within the first 2 years of life. Some children never walk
independently or speak, while others are slow to walk and/or
speak and then regress and lose the ability to walk indepen-
dently and/or speak. The disease progresses with upper limb,
bulbar, and pseudobulbar involvement to severe spastic
tetraparesis, anarthria, dysphagia, and slow eye movements
during the first decade of life. Wheelchair dependence occurs
in the second decade of life. Incontinence and feeding via a
gastrostomy have been described in some individuals in the
advanced stages of the disease [17]. Scoliosis, although re-
ported, is uncommon. Overall, cognitive function is preserved
in IAHSP, and the condition is compatible with long-term
survival. Muscle biopsy and nerve conduction velocities are
normal, and electromyography reveals no sign of denervation.
However, motor evoked potentials show signs of severe dys-
function of the corticospinal tracts, consistent with degenera-
tion of UMN. Somatosensory evoked potentials are normal in
the early stages and abnormal in later stages of the disease.
Brain MRI is normal in children, but older patients had corti-
cal atrophy (predominantly in the motor areas) and T2-weight-
ed bilateral hyperintensities in the corticospinal pathways of
the posterior arms of the internal capsule and brainstem. In
addition, T2 and FLAIR periventricular hyperintensities and
cervical cord atrophy that are frequently seen in other hered-
itary spastic paraplegias (HSPs) are commonly identified [4,
12].
The novel phenotype of JALS/ALS2 associated with gen-
eralized dystonia has previously been reported in two unrelat-
ed consanguineous families of Bangladeshi and Turkish de-
scent, with homozygous loss of function variants in ALS2
[26]. Shortly thereafter, the same phenotype was described
in a large consanguineous Pakistani family with a homozy-
gous splice site variant in ALS2 [27]. Other novel clinical
findings in the Bangladeshi family described in the first paper
[26] include microcephaly and cerebellar signs, but the au-
thors noted that it is unclear whether these features are caused
by the ALS2 pathogenic variant.
Our study provides one of the largest reported series and
includes the oldest reported individuals with IAHSP surviving
into their late 40s with preserved cognitive function and nor-
mal eye movements. To our knowledge, these are the first
Iranian cases affected by IAHSP and ALS2-related disorders.
Additionally, here, we report on the first family in the
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literature with IAHSP and generalized dystonia (family 2).
Despite having the identical homozygous ALS2 pathogenic
variant, these families demonstrate intra- and interfamilial
phenotypic variability, suggesting that environmental factors,
modifier genes, and/or epigenetic factors may play a role in
this condition.
In conclusion, we identified a novel ALS2 pathogenic foun-
der variant in Iran that further adds to the allelic heterogeneity
of IAHSP. The family with generalized dystonia expands the
phenotypic variability of IAHSP and ALS2-related disorders.
These findings also demonstrate the overlapping nature of
these allelic disorders. Future clinical and functional studies
are needed to better delineate genotype-phenotype
correlations.
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